Ocular toxicity of fludarabine: A purine analog

Expert Review of Ophthalmology

Volumn 3, Issue 1, 2008, Pages 97-109

  Ding, Xiaoyan ^a,b   Herzlich, Alexandra A ^a   Bishop, Rachel ^a   Tuo, Jingsheng ^a   Chan, Chi Chao ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Fludarabine; Neurotoxicity; Ocular toxicity; Ophthalmic pathology; Pharmacogenetics; Purine analog

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; FAMCICLOVIR; FLUDARABINE; IMMUNOMODULATING AGENT; MITOXANTRONE; PROTEIN KINASE C; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACUTE MONOCYTIC LEUKEMIA; ANEMIA; AREA UNDER THE CURVE; ATAXIA; BLINDNESS; BLURRED VISION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN DISEASE; BRAIN DYSFUNCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CEREBRAL BLINDNESS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMA; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTINUOUS INFUSION; DEMENTIA; DISORIENTATION; DIZZINESS; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; EYE TOXICITY; FATIGUE; FEVER; GASTRITIS; GASTROINTESTINAL DISEASE; HALLUCINATION; HEMOLYTIC ANEMIA; HUMAN; INFECTION; LEUKOENCEPHALOPATHY; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MENTAL DETERIORATION; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OPTIC NERVE ATROPHY; OPTIC NEURITIS; PAPILLITIS; PARALYSIS; PERIPHERAL NEUROPATHY; QUADRIPLEGIA; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; RETINA BIPOLAR GANGLION CELL; RETINA NECROSIS; RETINA VASCULITIS; REVIEW; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; SOMNOLENCE; SPINAL CORD DISEASE; THROMBOCYTOPENIA; TREMOR; UVEITIS; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VOMITING; WEAKNESS;

EID: 47249109074     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.3.1.97     Document Type: Review

References (60)

1. Blau IW, Schmidt-Hieber M, Leschinger N et al. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation. Ann. Hematol. 86(8), 583-589 (2007).
2. Karp JE, Giles FJ, Gojo I et al. A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP. Triapine® in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leuk. Res. 32(1), 71-77 (2007).
3. Montgomery JA, Hewsoi K. Nucleosides of 2-fluoroadenine. J. Med. Chem. 12(3), 498-504 (1969).
4. Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 53(6), 1005-1037 (1997).
5. Plosker GL, Figgirt DP. Oral fludarabine. Drugs, 63(21), 2317-2323 (2003).
6. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin. Pharm. 41(2), 93-103 (2002).
7. Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL,Jr. In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol. Pharmacol. 21(2), 474-477 (1982).
8. White EL, Shaddix SC, Brockman RW, Bennett LL, Jr. Comparison of the actions of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res. 42(6), 2260-2264 (1982).
9. Avramis VI, Plunkett W. Metabolism of 9-β-D-arabinosyl-2-fluoroadenine-5′-phosphate by mice bearing P388 leukemia. Cancer Drug Deliv. 1(1), 1-10 (1983).
10. Noker PE, Duncan GF, El Dareer SM, Hill DL. Disposition of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-phosphate in mice and dogs. Cancer Treat. Rep. 67(5), 445-456 (1983).
11. Keating MJ, O'Brien S, McLaughlin P et al. Clinical experience with fludarabine in hemato-oncology. Hematol, Cell Ther. 38(Suppl. 2), S83-S91 (1996).
12. Malspeis L, Griever MR, Staubus AE, Young D. Pharmacokinetics of 2-F-ara-A (9-β-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the Phase I clinical investigation of fludarabine phosphate. Semin. Oncol. 17(5 Suppl. 8), 18-32 (1990).
13. Hersh MR, Kuhn J G, Phillips JL et al. Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother. Pharmacol. 17(3), 277-280 (1986).
14. Lichtman SM, Etcubanas E, Budman DR et al. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Invest. 20(7-8), 904-913 (2002).
15. Gandhi V, Kemena A, Keating MJ, Plunkett W. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk. Lymphoma 10(1-2), 49-56 (1993).
16. Foran JM, Oscier D, Orchard, J et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with 'low-grade' non-Hodgkin's lymphoma and B-cett chronic lymphocytic leukemia. J. Clin. Oncol. 17(5), 1574-1579 (1999).
17. Oscier D, Orchard JA, Culligan D et al. The bioavailability of oral fludarabine phosphate is unaffected by food. Hematol. J. 2(5), 316-321 (2001).
18. Yildiz O, Ozguroglu M, Yanmaz MT et al. Paraneoplastic pemphigus associated with fludarabine use. Medical oncology 24(1), 115-118 (2007).
19. Johnson S, Smith AG, Loffler H et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 347(9013), 1432-1438 (1996).
20. Montillo M, Ricci F, Tedeschi A. Role of fludarabine in hematological malignancies. Expert Rev. Anticancer. Ther. 6(9), 1141-1161 (2006).
21. Anaissie EJ, Kontoyiannis DP, O'Brien S et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann. Intern. Med. 129(7), 559-566 (1998).
22. Girmenia, C, Mauro FR, Rahimi S. Late listeriosis after fludarabine plus prednisone treatment. Br. J. Haematol. 87(2), 407-408 (1994).
23. Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF. Central nervous system toxicity of fludarabine phosphate. Cancer Treat. Rep. 70(10), 1225-1228 (1986).
24. Spriggs DR, Stopa F, Mayer RJ, Schoene W, Kufe DW. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res. 46(11), 5953-5958 (1986).
25. Warrell RP Jr, Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol. 4(1), 4-79 (1986).
26. Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: a review. J. Clin. Oncol. 12(10), 2216-2228 (1994).
27. Grever M, Leiby J, Kraut E et al. A comprehensive Phase I and II clinical investigation of fludarabine phosphate. Semin. Oncol. 17(5 Suppl. 8), 39-48 (1990).
28. Von Hoff DD. Phase I clinical trials with fludarabine phosphate. Semin. Oncol. 17(5 Suppl. 8), 33-38 (1990).
29. Grever MR, Kopecky KJ, Coltman CA et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv. Rev. Fr. Hematol. 30(5-6), 457-459 (1988).
30. Montserrat E, Lopez-Lorenzo JL, Manso F et al. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. Leuk. Lymphoma 21(5-6), 467-472 (1996).
31. O'Brien ME, Matutes E, Cunningham D et al. Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience. Leuk. Lymphoma 14(Suppl. 2), 17-23 (1994).
32. Morgan AE. Chemotherapy-induced neurotoxicity. Cancer Control 2(3), 235-242 (1995).
33. Chee YL, Culligan DJ, Olson JA et al. Sight-threatening varicella zoster virus infection after fludarabine treatment. Br. J. Haematol. 110 1), 874-875 (2000).
34. Sorensen JM, Vena DA, Fallavollita A, Chun HG, Cheson BD. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J. Clin. Oncol. 15(2), 458-465 (1997).
35. Stillman M, Navia B, Mast J. Delayed neurotoxicity associated with fludarabine. Neurology, 35(Suppl. 1), 291 (1985).
36. Di Gaetano N, Xiao Y, Erba E et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Haematol. 114(4), 800-809 (2001).
37. Seymour JF, Huang P, Plunkett W, Ganchi V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine; implications for a continuous infusion schedule. Clin. Cancer Res. 2(4), 653-658 (1996).
38. Santini V, D'Ippolito G, Bernabei PA et al. Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement. Leuk. Res. 20(1), 37-45 (1996).
39. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol. 11(1), 116-124 (1993).
40. Kornblau SM, Cortes-Franco J, Estey E. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia, 7(3), 378-383 (1993).
41. Flinn JW, Neuberg DS, Grever MR et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol. 25(7), 793-798 (2007).
42. Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lyphocytic leukaemia (the i RF CLL4 Trial): a randomised controlled trial. Lancet, 370(9583), 230-239 (2007).
43. Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343(24), 1750-1757 (2000).
44. Von Hoff DD, Green S, Surwit EA, Hannigan EV, Alberts DS. Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology Group study. Am. J. Clin. Oncol. 13(5), 433-435 (1990).
45. Chanan-Khan A, Miller KC, Takeshita K et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood, 106(10), 3348-3352 (2005).
46. Giannopoulos K, Dmoszynska A, Rolinski J. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia. Leuk. Res. 31(3), 411-412 (2007).
47. Tam CS, Seymour JF, Prince HM et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 91(11), 1546-1550 (2006).
48. +-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J. Biol. Chem. 276(4), 2914-2927 (2001).
49. Mangravite LM, Badagnani I, Giacomini KM. Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. Eur. J. Pharm. 479(1-3), 269-281 (2003).
50. Nagase K, Tomi M, Tachikawa M, Hosoya K. Functional and molecular characterization of adenosine transport at the rat inner blood-retinal barrier. Biochim. Biophys. Acta 1758(1), 13-19 (2006).
51. Badagnani I, Chan W, Castro RA et al. Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 ( CNT3; SLC28A3). Pharmacogenomics J. 5(3), 157-165 (2005).
52. Gray JH, Mangravite LM, Owen RP et al. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol. Pharmacol. 65(3), 512-19 (2004).
53. Hutton JJ, Von Hoff DD, Kuhn J et al. Phase I clinical investigation of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res. 44(9), 4183-4186 (1984).
54. Harvey WH, Fleming TR, Von Hoff DD, Katterhagen JG, Coltman CA Jr. Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study. Cancer Treat. Rep. 71(12), 1319-1320 (1987).
55. Balducci L, Blumenstein B, Von Hoff DD et al. Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study. Cancer Treat. Rep. 71(5), 543-544 (1987).
56. Weiss GR, Crowley J, Von Hoff DD et al. Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study. Cancer Treat. Rep. 70(9), 1123-1124 (1986).
57. Rainey JM, Hill JB, Crowley J. Evaluation of fludarabine phosphate in small cell carcinoma. A Southwest Oncology Group Study. Invest. New Drugs 6(1), 45-46 (1988).
58. Kantarjian HM, Childs C, O'Brien S et al. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am. J. Med. 90(2), 223-228 (1991).
59. Hochster HS, Kim KM, Green MD et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 10(1), 28-32 (1992).
60. Cohen RB, Abdallah JM, Gray JR, Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann. Intern. Med. 118(2), 114-116 (1993).